Today: 3 March 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

You Won’t Believe Alabama Power’s Halloween Projects: Debunking “Energy Vampires” & Saving Bats

You Won’t Believe Alabama Power’s Halloween Projects: Debunking “Energy Vampires” & Saving Bats

Southern Company, parent of Alabama Power, reported Q3 2025 net income of $1.7 billion, up from $1.5 billion a year earlier. Alabama Power marked Halloween by debunking energy-saving myths and warning about “energy vampires” from idle electronics. Employees built 30 bat houses for Bat Week to aid local bat populations. Southern’s stock trades near a 52-week high as the company invests in new gas-fired generation.
31 October 2025
·
China’s Soybean Buying Spree After Trade Truce Thrills Farmers, Shakes Markets

China’s Soybean Buying Spree After Trade Truce Thrills Farmers, Shakes Markets

China agreed to buy 12 million metric tons of U.S. soybeans by January and 25 million tons annually for three years under a trade truce announced Oct. 30. State grain trader COFCO purchased the first U.S. soybeans of the year just before the Trump-Xi summit. Chicago soybean futures hit 15-month highs on the news. Analysts say the deal restores pre-trade-war levels but warn tariff issues remain unresolved.
31 October 2025
··
Marvell Technology Stock Soars on AI Boom: Latest Price, Hot News & 2025 Outlook

Marvell Technology Stock Soars on AI Boom: Latest Price, Hot News & 2025 Outlook

Marvell Technology shares trade in the high-$80s, down about 20% year-to-date but up 15–20% from last fall. The stock jumped over 5% in late October after Amazon cited strong demand for Trainium AI chips, which Marvell helps produce. About 74% of Marvell’s revenue now comes from cloud data center products, with AI-related sales rising rapidly. Marvell faces competition from Broadcom, Nvidia, and AMD in cloud and AI chips.
31 October 2025
·
Getty Images Stock Soars on AI Deal – A $1 Billion Visual Content Giant’s 2025 Outlook Revealed

Getty Images Stock Soars on AI Deal – A $1 Billion Visual Content Giant’s 2025 Outlook Revealed

Getty Images (NYSE: GETY) surged nearly 40–50% intraday on October 31, 2025, after announcing a major AI partnership, closing at $2.82 per share and valuing the company at around $1.1–1.2 billion. Shares remain about 30% below year-ago levels despite a 60% gain over the past quarter. Getty reported Q2 2025 revenue of $234.9 million and a net loss, with EBITDA margins near 30%. The company holds over $1.3 billion in debt after recent refinancing.
31 October 2025
···
Former Deloitte Chair Joins Conduent Board – Can His Expertise Turn the Tide?

Former Deloitte Chair Joins Conduent Board – Can His Expertise Turn the Tide?

Michael J. Fucci, former Deloitte US Chair, has joined Conduent’s Board of Directors effective October 27. The appointment comes as Conduent’s stock trades near 52-week lows after a 30% drop this year and a recent credit downgrade. Fucci brings four decades of leadership experience, including current board roles at Acadia Healthcare and Flotek Industries. Investors await Conduent’s Nov. 7 earnings for signs of a turnaround.
31 October 2025
·
Roku’s Stunning Comeback – Stock Soars to 52-Week High on Profit Surprise and Amazon Deal

Roku’s Stunning Comeback – Stock Soars to 52-Week High on Profit Surprise and Amazon Deal

Roku shares hit a 52-week high of $107.57 on Oct. 31, 2025, after reporting Q3 revenue of $1.21 billion and its first quarterly profit since 2021. The company raised its full-year outlook, authorized a $50 million buyback, and announced an exclusive ad partnership with Amazon. Roku also expanded its smart TV presence in Europe through a deal with Vestel.
31 October 2025
··
MultiSensor AI’s Wild Stock Ride: Major AI Deal Sparks 42% Surge, $14M Funding Triggers 50% Plunge – What’s Next for MSAI?

MultiSensor AI’s Wild Stock Ride: Major AI Deal Sparks 42% Surge, $14M Funding Triggers 50% Plunge – What’s Next for MSAI?

MultiSensor AI shares soared over 40% after announcing a major U.S. deployment with a global e-commerce logistics firm, then plunged nearly 50% following news of a $14 million private placement at $0.41 per share. The stock rebounded to $2.05 on Oct. 31, 2025, up 55% intraday. Wall Street analysts rate the stock a “Strong Buy” with an average $2.75 target. 2024 revenue was $7.4 million with a $21.5 million net loss.
31 October 2025
··
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie reported Q3 2025 revenue of $15.78 billion, up 9.1% year-over-year, and raised its full-year EPS outlook after new drugs offset Humira’s decline. Shares traded near $228 in late October, up 28% year-to-date, and the board approved a 5.5% dividend increase for 2026. Skyrizi and Rinvoq sales surged, while the FDA expanded Rinvoq’s indications. AbbVie also announced over $10 billion in acquisitions and new manufacturing investments.
31 October 2025
··
Dueling Dinosaurs Fossil Shocks Scientists: ‘Teenage T. rex’ Was a New Species All Along

Dueling Dinosaurs Fossil Shocks Scientists: ‘Teenage T. rex’ Was a New Species All Along

Researchers confirmed Nanotyrannus was a distinct tyrannosaur species that lived alongside T. rex, not a juvenile T. rex, after analyzing the “Dueling Dinosaurs” fossil. The study identified two Nanotyrannus species, both smaller and anatomically different from T. rex. Findings overturn decades of assumptions about young T. rex fossils and force a reexamination of tyrannosaur evolution.
31 October 2025
Jack’s Donuts Bankruptcy Shakes Indiana – 64-Year-Old Doughnut Chain Faces Uncertain Future

Jack’s Donuts Bankruptcy Shakes Indiana – 64-Year-Old Doughnut Chain Faces Uncertain Future

Jack’s Donuts of Indiana Commissary, LLC filed for Chapter 11 bankruptcy on Oct. 29, 2025, listing $14.2 million in liabilities and $1.4 million in assets. Franchise locations remain open and are not affected by the filing. The bankruptcy follows a failed expansion into centralized production and legal action against CEO Lee Marcum for alleged securities violations. Marcum’s other companies also filed for bankruptcy the same day.
31 October 2025
·
Vivakor (VIVK) Stock Skyrockets on Oil Deal and Trading Debut – Will the Rally Last?

Vivakor (VIVK) Stock Skyrockets on Oil Deal and Trading Debut – Will the Rally Last?

Vivakor shares surged nearly 20% to $0.32 intraday on October 30, 2025, after announcing a $24 million Permian Basin crude oil deal and securing a $40 million credit facility. The Dallas firm also raised $3.5 million in new equity and saw its lender convert $1.45 million of debt into shares, diluting existing holders. VIVK trades below Nasdaq’s $1 minimum and posted a $22 million loss in 2024.
30 October 2025
··
Cardinal Health (NYSE: CAH) Stock Soars to Record High on Blowout Earnings and Raised Outlook

Cardinal Health (NYSE: CAH) Stock Soars to Record High on Blowout Earnings and Raised Outlook

Cardinal Health shares jumped 13% to record highs near $185 after fiscal Q1 2026 results beat estimates, with adjusted EPS at $2.55 and revenue at $64.0 billion. The company raised its full-year outlook and announced a $375 million buyback. All five segments grew profits, marking an eighth straight earnings beat. Cardinal plans to close the Solaris Health acquisition by early November.
30 October 2025
··
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis Pharmaceuticals reported Q3 2025 revenue of $458.6 million and a $215.7 million net profit, but its stock fell about 21% after management warned of future losses. Syfovre sales in the U.S. were flat at $150.9 million, with modest injection growth and ongoing debate over its benefits. Empaveli gained FDA approval for rare kidney diseases in July. Analyst ratings and price targets remain divided.
30 October 2025
·
1 … 52 53 54 55 56 … 140
Go toTop